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AND F. X. S. EMMANUEL 
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C-reactive protein (CRP) has been shown to be a useful and sensitive indicator of pyogenic infections in many 
clinical situations, including acute pneumonia and infective pulmonary exacerbations in cystic fibrosis patients. 
Exacerbations of COPD are often, but not always, associated with demonstrable infection. The value of CRP 
measurement in this situation has not been assessed. 
We have evaluated CRP measurement in 50 patients [age 71 * 8 (SD) years] who were admitted to hospital with 
clinical evidence of exacerbation [PaO,=7.3 * 1.3 (SD) kPa, baseline FEV, =0.8 & 0.4 (SD) 11. These patients all had 
serial measurement of CRP [polarizing immunofluorescence (Abbot, TDx)], peripheral white cell count (WCC), 
body temperature, peak expiratory flow rate, Karnofsky performance status and chest X-ray, in addition to serial 
sputum bacteriological analysis carried out in a specialized laboratory. 
CRP was elevated (> 10 mg 1 - ‘) in all patients (n=29) with proven infection [103 & 98 (SD) mg 1~ ‘I. Levels were 
markedly elevated in patients infected with Streptococcuspneumoniae (mean 156 mg l- ‘); there was also a rapid fall 
in the CRP with therapy. WCC fell with therapy, giving a correlation with CRP level (v=O.44, P<O.Ol). 
Since CRP elevation was observed in patients having exacerbation with proven infections and also in those where 
infection was not proven, it is possible that, while it is a marker for COPD exacerbation, it is not necessarily a 
marker of bacterial infection per se. However, it is evident from our study that it is of value in the assessment of 
exacerbations of COPD, where routine bacterial culture of sputum is often unreliable, and thus the measurement of 
serum CRP may provide an additional objective indicator of infection. 
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Introduction 
C-reactive protein (CRP) is one of the most dramatic 
acute-phase reactants of man. It may increase as much as 
2000 times in certain diseases, which suggests a significant 
biological function. Its main clinical usefulness lies in its 
ability to reveal early inflammation and tissue injury when 
other clinical parameters are equivocal (1,2). 
CRP estimation has been shown to be a useful and 
sensitive indicator of pyogenic infections in many clinical 
conditions including acute pneumonia, neonatal septicae- 
mia (3) and meningitis (4) and also intercurrent infections in 
leukaemia and systemic lupus erythematosus (1,2). More 
recently, it has been shown that an elevated CRP level is a 
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useful indicator of exacerbations in cystic fibrosis patients 
with chronic bronchiectasis (5,6). 
Exacerbations of chronic obstructive pulmonary disease 
(COPD) account for one of the commonest causes of 
hospital admissions for patients, especially during the 
winter months. Exacerbations are often, but not always, 
associated with clinical and laboratory evidence of infection 
(7,8). Many patients with COPD are chronically colonized 
with potential bacterial pathogens such as Huemophilus 
injfuenzae and Streptococcus pneumoniae, and thus routine 
bacteriological culture of sputum may sometimes be un- 
reliable although the patients improve clinically. Thus, on 
the basis of routine bacteriological sputum culture, there 
may be difficulty in distinguishing colonization from active 
infection and even in assessing the efficacy of antimicrobial 
therapy. 
To our knowledge there have been no studies to assess 
the value of measuring CRP in clinical exacerbations of 
COPD. Since CRP is reliable and easily quantifiable and 
has been shown to be useful in other infections, our aim in 
this study was to ascertain whether infective exacerbations 
and their successful treatment correlate with corresponding 
changes in CRP levels. 
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Patients and Methods 
Fifty patients [age 71 * 8 (SD) years] with diagnosed COPD 
on the basis of clinical history and pulmonary function tests 
were studied. All 50 patients were admitted to the City 
Hospital, Edinburgh, because of clinical exacerbation of 
their condition with dyspnoea and increased cough with 
expectoration of yellow-green sputum. All of them had 
significant hypoxaemia [PaO,=7.3 f 1.3 (SD) kPa] and a 
baseline FEV, of 0.8 + 0.4 (SD) 1. Pneumonia was excluded 
by clinical examination and chest radiograph. 
Serum samples were obtained on admission from the 
patients for measurements of CRP and full blood count, 
together with sputum samples for microbiological examina- 
tion. Serum samples were obtained for CRP levels from 
another control group of 22 patients with COPD who were 
stable and were not in exacerbation. Patients in the control 
group were selected from those attending the outpatients’ 
clinic. The criteria used for inclusion in the control group 
were stable pulmonary status, with a baseline FEV, of > 1 1, 
with no symptoms or signs suggesting exacerbation, and no 
antibiotic therapy in the previous 48 h. 
All the patients in exacerbation were treated with 
bronchodilators, controlled oxygen therapy and broad- 
spectrum antibiotics and with diuretics for any associated 
cardiac failure. Repeat blood and sputum samples were 
obtained for CRP estimation, full blood count and micro- 
biological analysis, after 4-5 days of antibiotic therapy. The 
clinical and radiological statuses were also reviewed at this 
time. 
Laboratory Methods 
Expectorated sputum samples were examined by Gram 
stain and accepted as suitable for culture if they satisfied 
both the following criteria: 
1. < 10 squamous epithelial cells per low-power field 
( X 100 magnification); 
2. >25 alveolar macrophages and/or polymorphonuclear 
cells per low-power field. 
An average value was taken after examination of five fields. 
Validated samples were cultured on (a) Columbia-base 
blood agar with 8% horse blood and (b) heated blood agar 
(8% horse blood) with 10 units bacitracin ml ~ ‘. Both plates 
were incubated in an atmosphere of 8% CO,. 
Virological tests were not done as part of the study. 
Serum samples were first screened using the CRP- 
Wellcotest latex agglutination test (Wellcome Diagnostics). 
The upper limit of the normal range of this test is set at 
CRP 10 mg 1 - ‘. Negative samples were subsequently 
screened at 1110 dilution to exclude false-negative reactions 
which may occur in sera with very high CRP levels. All 
samples positive by latex agglutination were then quantita- 
tively analysed by the polarizing immunofluorescence 
method (Abbot TDx). CRP levels of 10 mg 1 - ’ or less were 
regarded as within the normal range. 
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FIG. 1. Peak CRP levels (-@--, mean) in patients from 
whom H. influenzae, S. pneumoniae and Moraxella 
catawhalis were isolated. Note high CRP values in 
M. catarrhalis. 
Results 
CRP levels were elevated (>lO mg l- ‘) in all patients 
(TI= 29) where recognized bacterial pathogens were isolated, 
and in 13 of the 21 patients (62%) with no clear bacterio- 
logical evidence of infection (Fig. 1). The average elevated 
CRP level in the former group was 103 & 98 (SD) mg l- r 
(range 20-388 mg l- ‘); the average CRP level of the latter 
group was 92 & 90 (SD) mg l- ’ (range ~10-324 mg l- ‘). 
None of the group of control patients who were not in 
exacerbation (n = 20) showed CRP levels of > 10 mg l- r. 
The list of aetiological bacteria cultured from patients in 
the infective group is shown in Table 1; with H. injfuenzae, 
S. pneumoniae and M catarvhalis being the three most 
common organisms. The group of 13 patients without any 
clear bacteriological evidence of infection who showed a 
raised CRP level responded well to treatment with anti- 
biotics with an accompanying fall in CRP levels (Fig. 2). 
The average CRP level after adequate treatment was 
33 + 4 (SD) mg 1 - ’ (P<O.OOl). The peak CRP level and fall 
in CRP were both correlated with the corresponding 
peripheral blood white cell count (r=0,44, P<O.Ol). CRP 
levels were markedly elevated in patients infected with 
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TABLE 1. Bacterial species cultured from sputum from 
patients with COPD 
Aetiological bacteria 
H. injluenzae 10 
S. pneumoniae 5 
M catarrhalis 5 
Pseudomonas spp. 4 
Staphylococcus aureus 2 
Mixed infections 
H. influenzae + S. pneumoniae 2 
H. influenzae + M. catarvhalis 1 
Total number of patients with identified pathogens 29 
Proven infection No bacterial pathogen 
isolated 
FIG. 2. CRP levels before and after 4-5 days of treatment 
in patients with proven bacterial infection (n=29) and in 
patients without any clear evidence of bacterial pathogens 
(n=21). 
S. pneumoniae (mean 150 mg 1 - ‘) and in M catavvhalis 
infection (mean 190 mg l- ‘) (Fig. 1). 
All patients recovered from their exacerbation of chronic 
bronchitis and were discharged from hospital. During 
their stay in the hospital there was an improvement in their 
clinical condition and objective improvements in their 
arterial saturation from 7.3 & 1.3 (SD) kPa to a mean 
8.6 & 1.4 (SD) kPa. There was an improvement in their 
measured FEV, from 0.8 i 0.42 (SD) 1 before treatment to a 
mean of 1.1 f 0.2 1 after treatment (PCO.001). 
The statistical analysis was done using the Wilcoxon 
Mann-Whitney test. 
Discussion 
CRP is an acute-phase protein, which, when elevated, 
provides good evidence of an active tissue-damaging 
process. Thus its measurement provides a simple screening 
test for active organic disease. Increased CRP production 
is a very early and sensitive response to most forms of 
bacterial infections (1). Studies have shown that it can be 
a useful indicator in differentiating between bacterial 
meningitis and viral meningitis (38). CRP levels also have 
been previously found to be of value in discriminating 
between bacterial and viral pneumonia (8). 
In one study by Nel et al. (9) in addition to showing 
moderately increased levels in patients with exacerbations 
of bronchiectasis, they showed a significantly increased 
level of CRP during infective exacerbations in emphysema. 
More recently, other studies have shown CRP to be a useful 
indicator of exacerbations in cystic fibrosis patients (5,6). 
However, there has not been any assessment of the value of 
CRP in exacerbations of COPD, which is one of the 
commonest causes of hospital admissions in the United 
Kingdom. In this context, routine bacteriological analysis 
of sputum is often unreliable and slow. It is well established 
that the respiratory tract may be asymptomatically 
colonised; for example Pseudomonas aeruginosa in cystic 
fibrosis (5) or Haemophilus influenzae in chronic bronchitis 
(10,ll). Thus it may be difficult to distinguish active infec- 
tion from colonization on the basis of sputum culture. In 
this situation, serial CRP assays which are cheap, sensitive 
and rapid to perform provide a useful quantitative measure 
of exacerbation in COPD. 
Our study showed that in’most of the patients (84%) who 
had exacerbations of COPD, there was an elevated CRP 
at the time of admission to the hospital, whereas patients 
in the control group with stable COPD and not in 
exacerbation invariably had normal CRP levels. 
There were two groups of patients who had 
exacerbations of COPD, one with proven bacterial infec- 
tion and the other in which we were unable to implicate a 
bacterial cause of infection. However, in both of these 
groups, CRP was elevated. It is of interest to note that, in 
the latter group, although their sputum was bacterio- 
logically negative, they all clinically improved during their 
hospital stay with an associated dramatic fall in their CRP 
levels. This only reiterates the view that positive bacterio- 
logical results are not the only or most dependable 
parameter of exacerbation of COPD. Patients may have an 
infective exacerbation clinically, although their sputum 
does not grow any unequivocal pathogens. The reasons for 
this could be various, ranging from inadequate, improper 
sputum sampling to problems with analysis or even unusual 
behaviour of the strains. It is also possible that viral 
infection could be a pathogenetic factor in patients from 
whom the sputum were negative for bacterial pathogens. 
Conversely, some patients may be chronically colonized 
with potential bacterial pathogens, which are behaving as 
commensals (11). Thus microbiological examination of 
sputum may not always be a useful indicator of active 
infective state. Since both of the groups with clinical 
exacerbation had their CRP levels elevated initially and had 
clinical improvement with lowering of the CRP levels after 
treatment, there is a strong possibility that CRP is a marker 
of an exacerbation of COPD but not necessarily a marker 
of bacterial infection. As well as antibiotics, the fall in CRP 
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together with the clinical improvement could be due to 
several other factors, e.g. bronchodilators, oxygen or 
spontaneous recovery. Eight of the patients, however, did 
not show a rise in CRP despite having clinical evidence of 
clinical exacerbation. We were unable to detect any evi- 
dence of bacterial infection in these patients. There was a 
similar small group of patients with emphysema in the 
study by Nel et al. (9) who appeared to have normal CRP 
during exacerbation. It is possible that these patients might 
have had viral infections which sometimes do not cause 
elevation of CRP or have some other physiological defect 
that interferes with CRP response. However, in the 
majority of patients CRP was elevated during exacerbation, 
and levels fell to normal range with appropriate treat- 
ment, thus providing a useful objective assessment of 
exacerbation. 
It is of interest that those patients who grew M. 
catavhalis in their sputum had particularly high CRP 
levels. This organism has lately been recognized as a 
pathogen causing exacerbations of COPD (12) and pre- 
vious reports have doubted its virulence (13). Our demon- 
stration of CRP response is further support for the view 
that this organism can be a cause of exacerbation of COPD. 
We suggest that, in exacerbations of COPD, CRP esti- 
mation provides a useful and inexpensive early marker of 
the exacerbation and provides a useful guide to assess the 
efficacy of treatment. 
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